SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-476287"
 

Search: onr:"swepub:oai:DiVA.org:uu-476287" > Prognostic Signific...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Khadse, AnandOslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway.;Univ South Eastern Norway, Fac ofTechnol, Dept Nat Sci & Environm Hlth, Nat Sci & Maritime Sci, Bo, Telemark, Norway. (author)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2022-04-29
  • Frontiers Media S.A.2022
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-476287
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-476287URI
  • https://doi.org/10.3389/fonc.2022.873532DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Lung cancer is a common disease with a poor prognosis. Genomic alterations involving the KRAS gene are common in lung carcinomas, although much is unknown about how different mutations, deletions, and expressions influence the disease course. The first approval of a KRAS-directed inhibitor was recently approved by the FDA. Mutations in the KRAS gene have been associated with poor prognosis for lung adenocarcinomas, but implications of the loss of heterozygosity (LOH) of KRAS have not been investigated. In this study, we have assessed the LOH of KRAS in early-stage lung adenocarcinoma by analyzing DNA copy number profiles and have investigated the effect on patient outcome in association with mRNA expression and somatic hotspot mutations. KRAS mutation was present in 36% of cases and was associated with elevated mRNA expression. LOH in KRAS was associated with a favorable prognosis, more prominently in KRAS mutated than in wild-type patients. The presence of both LOH and mutation in KRAS conferred a better prognosis than KRAS mutation alone. For wild-type tumors, no difference in prognosis was observed between patients with and without LOH in KRAS. Our study indicates that LOH in KRAS is an independent prognostic factor that may refine the existing prognostic groups of lung adenocarcinomas.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Haakensen, Vilde D.Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway.;Oslo Univ Hosp, Dept Oncol, Oslo, Norway. (author)
  • Silwal-Pandit, LaxmiOslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway. (author)
  • Hamfjord, JulianOslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway.;Oslo Univ Hosp, Dept Oncol, Oslo, Norway. (author)
  • Micke, PatrickUppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab(Swepub:uu)patmi676 (author)
  • Botling, JohanUppsala universitet,Science for Life Laboratory, SciLifeLab,Institutionen för immunologi, genetik och patologi(Swepub:uu)johanbot (author)
  • Brustugun, Odd TerjeOslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway.;Vestre Viken Hosp Trust, Drammen Hosp, Sect Oncol, Drammen, Norway. (author)
  • Lingjaerde, Ole ChristianOslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway.;Univ Oslo, Ctr Bioinformat, Dept Informat, Oslo, Norway. (author)
  • Helland, AslaugOslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway.;Oslo Univ Hosp, Dept Oncol, Oslo, Norway.;Univ Oslo, Dept Clin Med, Oslo, Norway. (author)
  • Kure, Elin H.Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway.;Univ South Eastern Norway, Fac ofTechnol, Dept Nat Sci & Environm Hlth, Nat Sci & Maritime Sci, Bo, Telemark, Norway. (author)
  • Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway.;Univ South Eastern Norway, Fac ofTechnol, Dept Nat Sci & Environm Hlth, Nat Sci & Maritime Sci, Bo, Telemark, Norway.Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway.;Oslo Univ Hosp, Dept Oncol, Oslo, Norway. (creator_code:org_t)

Related titles

  • In:Frontiers in Oncology: Frontiers Media S.A.122234-943X

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view